Adverse Reactions
Recently Published Documents


TOTAL DOCUMENTS

5952
(FIVE YEARS 2260)

H-INDEX

105
(FIVE YEARS 27)

2021 ◽  
Vol 2021 ◽  
pp. 1-9
Author(s):  
Chenxi He ◽  
Fanting Kong ◽  
Xinying Zhu ◽  
Fanlei Kong ◽  
Wei Zhao ◽  
...  

Studies have shown that COX-2 expression is upregulated in gastric cancer (GC) as well as in precancerous lesions and in Helicobacter pylori-induced inflammation, suggesting that cyclooxygenase-2 (COX-2) may play an important role in gastric carcinogenesis. We attempted to investigate the role of clarithromycin with tinidazole on Helicobacter pylori-related gastritis from the aspects of clinical effect and COX-2 expression. From January 2016 to January 2019, 130 patients with Helicobacter pylori-related chronic gastritis were collected and grouped into the observation group (OG) and the control group (CG). Altogether, 80 patients in the OG were treated with clarithromycin with tinidazole, while 50 patients in the CG were treated with amoxicillin with metronidazole. Clinical symptom improvement time, content of COX-2 and B cell lymphoma-2 (BCL-2), content of inflammatory factors interleukin-1 (IL-1), IL-4, and C-reactive protein (CRP), expression level of nutritional indicators serum albumin (ALB), realbumin (PA), and transferrin (TF), clearance of Helicobacter pylori, total effective rate, and incidence of adverse reactions were detected. Compared with the CG, the OG had shorter clinical symptom improvement time, lower COX-2 and Bcl-2, lower expression of inflammatory factors IL-1, IL-4, and CRP, higher expression of nutritional indicators ALB, TF, and PA, higher clearance rate of Helicobacter pylori, higher total effective rate, and lower incidence of adverse reactions. Clarithromycin combined with tinidazole can effectively improve the clinical effect of Helicobacter pylori-related gastritis and reduce the expression level of COX-2.


2021 ◽  
Vol 2021 ◽  
pp. 1-7
Author(s):  
Jianglei Zhang ◽  
Miao Li ◽  
Ze Chen ◽  
Jun OuYang ◽  
Zhixin Ling

Epirubicin, gemcitabine, and pirarubicin are widely used as first-line drugs for intravesical chemotherapy to prevent tumor recurrence after transurethral bladder tumor resection for non-muscle-invasive bladder cancer (NMIBC). However, which drug is better is less discussed. A total of 335 NMIBC patients administered intravesical chemotherapy underwent transurethral bladder tumor resection (TURBT) in our hospital from October 2015 to October 2019. After TURBT, all the patients received standard intravesical chemotherapy. Through clinical data collection and telephone follow-up, the tumor recurrence and adverse reactions of all patients after bladder perfusion treatment were counted. Recurrence was defined as new tumor appearance in the bladder. Of the 335 patients who underwent intravesical chemotherapy, 109 patients received epirubicin and 114 patients and 112 patients were given gemcitabine and pirarubicin, respectively. According to the general information of the patients, the patients were divided into intermediate-risk and high-risk bladder cancer and compared separately. There was no statistical difference in clinical and pathological features between different groups ( P > 0.05 ). The recurrence rate of intermediate-risk bladder cancer patients shows no difference between three groups ( P > 0.05 ). As for the high-risk bladder cancer patients, it is found that the 1-year recurrence rate between three groups was not statistically significant ( P > 0.05 ), whereas the 2-year recurrence rate of patients given gemcitabine (9.87%) was significantly lower than that of epirubicin (25.37%) and pirarubicin (24.32%), and the difference was statistically significant ( P < 0.017 , Bonferroni adjusted P value). The Kaplan–Meier survival curves showed that the recurrence-free survival rate of patients received gemcitabine was significantly higher than that of the other two groups. Comparing the incidence of adverse reactions during the infusion of the three groups of patients, the differences were not statistically significant ( P > 0.05 ). In patients with high-risk non-muscle-invasive bladder cancer, the application of gemcitabine intravesical chemotherapy is related with a relatively lower recurrence rate but similar incidence of adverse reactions.


2021 ◽  
Vol 5 (6) ◽  
pp. 73-77
Author(s):  
Xiaorui Zhu

Objective: To discuss and analyze the clinical effect of auricular point sticking in lung cancer chemotherapy. Methods: Sixty-two patients with lung cancer treated with chemotherapy in Suqian Traditional Chinese Medicine Hospital of Jiangxi Province were selected for case evaluation and analysis. The time span of the research was from June 2020 to June 2021. The patients were divided into two groups: a study group (n = 31) and a control group (n = 31) based on their medical record numbers. All the patients were treated with conventional western medicine before and after chemotherapy to prevent adverse reactions; however, the patients in the study group were also treated with auricular point sticking in addition to the former. The relevant indexes of the two groups were compared. Results: The incidence of adverse reactions was significantly lower in the study group compared to the control group (P < 0.05); the rate of symptomatic relief of the patients in the study group was higher than that of the control group (P < 0.05); the stress response indexes toward chemotherapy of the study group were better than those of the control group (P < 0.05). Conclusion: Auricular point sticking for patients with lung cancer who are receiving chemotherapy can reduce the incidence of adverse reactions, alleviate clinical symptoms, such as chest distress, asthma, and poor appetite, significantly alleviate stress response caused by chemotherapy, as well as promote the treatment effect; thus, it is worthy of promotion.


2021 ◽  
Vol 5 (6) ◽  
pp. 52-56
Author(s):  
Qin Si

Objective: To explore the effect of bevacizumab combined with neoadjuvant chemotherapy in advanced ovarian cancer and the occurrence of adverse reactions. Methods: A total of 80 patients with advanced ovarian cancer, treated in Affiliated People’s Hospital of Inner Mongolia Medical University from June 2019 to December 2020, were randomly divided into two groups. In the chemotherapy group, 40 patients were treated with neoadjuvant chemotherapy, while in the combined group, another 40 patients were treated with bevacizumab combined with neoadjuvant chemotherapy. The therapeutic effects were compared at the end of the treatment cycle. Results: There was no significant difference in the levels of CA125, CEA, and VEGF between the two groups before treatment. However, after the treatment cycle, the levels of CA125, CEA, and VEGF in the combined group were significantly better than those in the chemotherapy group (P < 0.05). At the same time, the incidence of adverse reactions of the chemotherapy group was 67.50%, which was significantly higher than that of the combined group (35.00%; P < 0.05). Conclusion: Bevacizumab combined with neoadjuvant chemotherapy for patients with advanced ovarian cancer has significant curative effect. The combined therapy reduces the levels of tumor markers and inflammatory factors, improves patients’ quality of life, as well as reduces adverse reactions. It has high clinical promotion value.


2021 ◽  
Vol 5 (6) ◽  
pp. 28-31
Author(s):  
Yingfeng Huang ◽  
Li Liu ◽  
Fang Fang

Objective: To explore the impact of comprehensive nursing intervention on the quality of intestinal preparation in the process of intestinal preparation for hospitalized patients undergoing colonoscopy. Methods: A total of 320 patients underwent colonoscopy in our department from January to June 2021. They were grouped by random number table. There were 160 cases in the control group and 160 cases in the observation group. The adverse reactions of intestinal preparation and the cleanliness of intestinal preparation were analyzed. Results: Through comprehensive nursing intervention, it can be found that the incidence of adverse reactions in the preparation of colonoscopy in the control group was 24.38%, and that in the observation group was 13.48%. The results showed that the incidence of adverse reactions in the preparation of colonoscopy was significantly lower than that in the control group (P < 0.05), which indicates that the difference was statistically significant. In the control group, 105 people qualified in intestinal cleanliness score (> 5 points) during enteroscopy preparation, and the cleanliness qualification rate was 65.63%. In the observation group, 139 people qualified in intestinal cleanliness score (> 5 points) during enteroscopy preparation, and the cleanliness qualification rate was 86.88%. The cleanliness qualification rate of enteroscopy preparation was significantly higher than that of the control group, and P < 0.05, which indicates that the difference was statistically significant. Conclusion: Comprehensive nursing intervention can promote the quality of preparation of patients for colonoscopy, improve the compliance of patients and improve the accuracy of examination effect.


2021 ◽  
Vol 5 (6) ◽  
pp. 98-101
Author(s):  
Xiaoyun Liu

Objective: To explore the effect of comprehensive nursing on patients with cervical cancer. Methods: A total of 100 cervical cancer patients, treated in Weihai Central Hospital from May 2020 to May 2021, were included in this study. The patients were cared for by different methods. They were divided into two groups, the control group and the experimental group, in which routine nursing and comprehensive nursing were given, respectively. The effect of the two different nursing methods on the patients were compared and analyzed. Results: After nursing intervention, the incidence of complications and the scores of depression and anxiety of the experimental group were significantly lower compared with the control group, P < 0.05. Conclusion: The application of comprehensive nursing among patients with cervical cancer has a positive significance on their recovery. It reduces the incidence of adverse reactions, improve patients’ negative emotions, and improve their satisfaction.


Author(s):  
Filippos Filippatos ◽  
Elizabeth-Barbara Tatsi ◽  
Charilaos Dellis ◽  
Nick Dessypris ◽  
Vassiliki Syriopoulou ◽  
...  

Children ◽  
2021 ◽  
Vol 8 (12) ◽  
pp. 1097
Author(s):  
Ja Un Moon ◽  
Ji Yoon Han

Neurodiagnostic investigation requirements are expanding for diagnostic and therapeutic purposes in children, especially in those with developmental delay/intellectual disability (DD/ID). Thus, determination of optimal sedatives to achieve successful sedation and immobility without further neurological compromise is important in children with DD/ID. The purpose of this study is to assess the effectiveness and adverse reactions of chloral hydrate (CH) for brain magnetic resonance imaging (B-MRI) in children with DD/ID compared to those with normal intelligence (NI). We performed a retrospective chart review of children aged from 1 day to 12 years who required elective sedation using CH for B-MRI. About 730 cases (415 with DD/ID and 315 with NI) of CH sedation were conducted for B-MRI. Children with DD/ID showed a higher failure rate (22%) than did those with NI (6%); additional CH and prolonged sedation time were required. There was no difference in incidence of adverse reactions between DD/ID and NI groups (p = 0.338). Older or heavier children with DD/ID (p = 0.036 and p = 0.013, respectively), as well as those diagnosed with epilepsy or neuropsychiatric disorders showed higher risk of sedation failure (p < 0.001 for each). In conclusion, CH was a suboptimal sedative drug for children with DD/ID compared with those with NI. Other alternative or supplementary sedatives should be taken into consideration especially for those vulnerable groups.


2021 ◽  
Author(s):  
Hua Zhao ◽  
Jie Zheng ◽  
Qin Wang ◽  
Yueqin Ai ◽  
Ying Zhao ◽  
...  

Abstract BackgroundTrastuzumab, a monoclonal antibody which binds to the extracellular domain of HER2, is the first biological drug approved for the treatment of HER2-positive breast cancer. However, trastuzumab exhibits a series of adverse reactions in clinic, including cardiac toxicity, nerve damage, mild edema, abnormal liver function, thrombocytopenia, etc.Case presentationWe reported an invasive ductal carcinoma of the breast patient with single dose trastuzumab treatment developed a rare severe edema in patient’s neck, face, chest, abdomen, and both upper limbs. One month after trastuzumab administration, the patient was given methylprednisone (80 mg/day) for 5 days. The edema in patient’s neck, face and both upper limbs was mildly reduced compared with before, but patient’s CT image showed no significant reduction of edema.ConclusionTrastuzumab has an adverse reaction of edema, but this severe edema is extremely rare. It is important to increase awareness of serious adverse reactions among oncologist, and treat such serious adverse reactions at an early stage may reduce further damage.


Sign in / Sign up

Export Citation Format

Share Document